Cabozantinib 
Ipsen
['cabo ', 'rcc,(-irccs),(-srcc),(-urcc)']
cassiope: single arm trial of cabo 60mg in arcc pts w/ prior vegf tx in 2l: dose modifications due to aes: 76-78% dose discontinuation: 49-54% median dose: 44-48 mg orr: 22% (2l), 38% ( 3l) pfs: 7.8 (2l), 8.7 mo ( 3l) os: 13 mo (2l), 17 mo ( 3l) #asco23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @MCG_Urology and @AUB_Lebanon 🇱🇧